HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brendel, A.J. Articles by Manciet, G. Search for Related Content PubMed PubMed Citation Articles by Brendel, A.J. Articles by Manciet, G.

Thallium-201 Imaging in the Follow-Up of Differentiated Thyroid Carcinoma

Service de Médecine Nucléaire, Hôpital Universitaire Pellegrin, Bordeaux, France

Correspondence: For reprints contact: Prof. A. J. Brendel, MD, PhD, Hôpital Universitaire Pellegrin, F-33076 Bordeaux, France.

ABSTRACT

Since thallium-201 imaging has been reported as a potential means of follow-up of patients with differentiated thyroid carcinoma (DTC) during on going thyroid suppression therapy, the authors evaluated the diagnostic sensitivity of this procedure in 31 patients known to have metastases or local recurrence. Among 51 tumor sites ²⁰¹Tl imaging had a detection rate of 45% whereas 84% was noted for imaging with ¹³¹I administered in therapeutic doses. Thus, even though the effectiveness of the two radionuclides is not strictly comparable due to the difference in the administered doses, Thallium imaging cannot be recommended as the only modality for the follow-up of patients with DTC. Six of the eight tumor sites negative with ¹³¹I were positive with ²⁰¹Tl (especially metastatic cervico-mediastinal lymph nodes). So ²⁰¹Tl imaging may particularly be helpful in localizing metastases or recurrences in patients with a negative ¹³¹I scan and abnormal levels of serum thyroglobulin.

FOOTNOTES

Presented in part at the 34th Annual Meeting of the Society of Nuclear Medicine, June 1987.

This article has been cited by other articles:

				T. Shiga, E. Tsukamoto, K. Nakada, K. Morita, T. Kato, M. Mabuchi, K. Yoshinaga, C. Katoh, Y. Kuge, and N. Tamaki Comparison of 18F-FDG, 131I-Na, and 201Tl in Diagnosis of Recurrent or Metastatic Thyroid Carcinoma J. Nucl. Med., March 1, 2001; 42(3): 414 - 419. [Abstract] [Full Text]

				R. J. Robbins, R. M. Tuttle, R. N. Sharaf, S. M. Larson, H. K. Robbins, R. A. Ghossein, A. Smith, and W. D. Drucker Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 619 - 625. [Abstract] [Full Text]